Jessie’s story, written by Bianca Bye.
It takes a village — and the right care team.
Jessie was 42 when she was diagnosed with stage IV EGFR-positive lung cancer. She’d never smoked. After months of symptoms doctors couldn’t explain — a relentless cough, night sweats, shoulder pain, panic attacks — she kept pushing for answers. When she finally got one, it changed everything.
Jessie is a producer. Producing, as she describes it, is about bringing great minds around a table to see something through. When she was diagnosed, she applied that same instinct to her care — building her medical team the way she builds a production, pulling in specialists from City of Hope, MD Anderson, and Stanford until she had the right people in the room. Her “A Team.”
What EGFR means in real life
An EGFR mutation means the cancer has a specific driver — and, in this case, a target. There are treatments built to go after it, and for many patients that changes everything about what treatment looks like. If you’re navigating a new diagnosis, our guide to biomarker and mutation-specific communities is a good place to start.
But it’s not a cure. For advanced-stage disease, it manages. And it comes with side effects that don’t get enough attention: brain fog, fatigue, and word-recall problems that can make you feel like a different version of yourself. As a busy working mom, cancer cuts right into the middle of your life. Jessie realized how much quality of life mattered and sought out supportive care to manage what she was experiencing. It has made all the difference.
The surgery question
Jessie wanted her primary tumor removed. She calls it the mothership — and she wanted it out.
She asked. She was told surgery for advanced lung cancer is rare and may be oversold. She went home deflated.
Two weeks later, everything changed. Her response to treatment had been so remarkable that the calculus shifted. Dr. Heymach, Chair of Thoracic Oncology at MD Anderson, explained it this way: even one, two, or three percent residual disease is still billions of cancer cells. Targeted treatment might control them — but there’s data supporting that, in some cases, getting them out is the better bet.
Her primary oncologist encouraged her to seek other perspectives. Another surgeon told her “absolutely not.” There was a lot to contemplate — sobering conversations about the reality of her situation that couldn’t be avoided.
Then she found thoracic surgeon Dr. Antonoff, who strongly believed Jessie was a candidate. Her team at MD Anderson reviewed her case meticulously. Surgery was scheduled.
It takes a village
Cancer doesn’t just happen to the person diagnosed. Jessie’s husband, Matt, has been her rock. While she focused on treatment, he took on everything else — the insurance calls, the Social Security hold music, the hours of administrative labor nobody sees. As Jessie puts it: she can treat the disease; he has to do everything else.
And then there are the family and friends — the ones who show up, pinch hit, and sit in the hard conversations with her.
Jessie jokes that she’ll probably have her medical ID revoked at multiple institutions for being such a pain. But she’ll tell you that having the right team behind her, and a support system that holds everything else together, is exactly what lets her push that hard. That, and a little self-proclaimed stubbornness.
Where she’s headed
What gives Jessie hope isn’t abstract — it’s the science: the research happening right now into how cancer cells evade treatment, clinical trials, the evolution of targeted therapies, and the real possibility that stage IV doesn’t have to mean what it used to.
Watch the full three-part series with Jessie on YouTube.
You’re not alone in this. If you were recently diagnosed, start here with our step-by-step guide for newly diagnosed patients — or meet more of our community on Faces of YLCI.
Want to understand EGFR better? Watch our EGFR biomarker video series.
This three-part series was made possible with support from Johnson & Johnson.
